RECURRENT CHOLANGIOCARCINOMA
Clinical trials for RECURRENT CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare cancers: olaparib targets IDH mutations
Disease control OngoingThis study tests whether the drug olaparib can shrink or slow the growth of advanced solid tumors that have IDH1 or IDH2 gene mutations, including certain brain tumors (gliomas) and bile duct cancers (cholangiocarcinoma). About 89 adults whose cancer has spread or not responded t…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:53 UTC
-
New hope for bile duct cancer: targeted drug trial launches
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or come back. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. The main goal is to see how many pa…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated May 26, 2026 06:50 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The goal is to find the best dose and see if the combination is safe and can shrink tumors. About 55…
Matched conditions: RECURRENT CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 22, 2026 13:50 UTC